Entrada Therapeutics (TRDA) reported positive preliminary data from Phase 1 clinical trial with ENTR-601-44 for Duchenne Muscular Dystrophy, ENTR-601-44-101. The company said ENTR-601-44 was well tolerated in healthy volunteers and showed significant plasma concentration, muscle concentration and exon skipping.
"We achieved the goals of the ENTR-601-44-101 trial, including the identification of a clinically relevant starting dose for the planned Phase 2 global patient study," said Dipal Doshi, CEO.
The company said it is on track to submit regulatory applications in the fourth quarter of 2024 to initiate separate global Phase 2 clinical trials for ENTR-601-44 in patients with Duchenne who are exon 44 skipping amenable and for ENTR-601-45 in patients with Duchenne who are exon 45 skipping amenable.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.